13 completed, 1 unknown, 1 withdrawn. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Unknown 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 7 |
Follow 4SC AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) domatinostat in combination with avelumab - Merkel Cell Carcinoma | Phase 2 | Withdrawn | 4SC AG | 2021-11-01 | 2021-11-18 | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat [14C]-resminostat - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | 4SC AG | 5 | 2021-10-12 | 2022-02-18 |
| Pre-operative Immunotherapy in Stage II-III Urothelial Cancer Nivolumab - Urothelial Carcinoma | Phase 1 | Completed | The Netherlands Cancer Institute | 15 | 2021-08-23 | 2025-03-05 |
| Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 domatinostat in combination with avelumab - Merkel Cell Carcinoma | Phase 2 | Completed | 4SC AG | 19 | 2020-10-13 | 2024-05-08 |
| Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) Domatinostat, Avelumab - Cancer, GI Cancer | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 75 | 2019-01-11 | 2019-02-05 |
| 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy 4SC-202 in combination with Pembrolizumab - Malignant Melanoma | Phase 1 / Phase 2 | Completed | 4SC AG | 40 | 2017-09-25 | 2022-02-04 |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) resminostat, Placebo - Mycosis Fungoides, Sezary Syndrome | Phase 2 | Completed | 4SC AG | 201 | 2016-11-01 | 2024-08-30 |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) 4SC-202 - Advanced Hematologic Malignancies | Phase 1 | Completed | 4SC AG | 36 | 2011-03-01 | 2015-04-01 |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma 4SC-201(Resminostat), FOLFIRI - Advanced Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | 4SC AG | 17 | 2011-01-01 | 2015-04-01 |
| Single Dose Study With 4SC-203 in Healthy Volunteers 4SC-203, Placebo - Acute Myeloid Leukemia | Phase 1 | Completed | 4SC AG | 60 | 2010-01-01 | 2011-01-13 |
| Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies 4SC-205 - Advanced and Incurable Solid Tumors, Malignant Lymphomas | Phase 1 | Completed | 4SC AG | 60 | 2010-01-01 | 2015-04-13 |
| Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma Resminostat (4SC-201) - Hodgkin's Lymphoma | Phase 2 | Completed | 4SC AG | 37 | 2009-12-01 | 2014-01-16 |
| SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis SC12267 (4SC-101), Placebo, Methotrexate - Rheumatoid Arthritis | Phase 2 | Completed | 4SC AG | 266 | 2009-11-01 | 2012-03-01 |
| 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma 4SC-201, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Completed | 4SC AG | 57 | 2009-07-01 | 2014-01-16 |
| SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease SC12267 (4SC-101) - Inflammatory Bowel Disease (IBD) | Phase 2 | Completed | 4SC AG | 34 | 2009-03-01 | 2011-05-18 |
Carcinoma, Merkel Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Sezary Syndrome (2) · Arthritis, Rheumatoid (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Crohn Disease (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1)
domatinostat (5) · avelumab (3) · resminostat (2) · vidofludimus (2) · Folic Acid (1) · IFL protocol (1) · Methotrexate (1) · Nivolumab (1) · Sorafenib (1) · pembrolizumab (1)
Germany (9) · Italy (4) · Netherlands (3) · Poland (3) · Romania (3) · United Kingdom (3) · Belgium (2) · Bulgaria (2) · Czechia (2) · France (2) · Spain (2) · Austria (1) · Greece (1) · Japan (1) · Switzerland (1)
Andreas Engert, Prof. MD (1) · David Cunningham (1) · Dirk Schadendorf, MD (1) · Frank Wagner, PD Dr. med. (1) · Jan Walewski, Prof. (1) · Klaus Herrlinger, Prof. (1) · Klaus Mross, PD Dr. med. (1) · M.S. van der Heijden, Dr. (1) · Michael Bitzer, Prof. MD (1) · Rudolf Stadler, Prof. (1)
PMID 20413687, PMID 23078909, PMID 26952006, PMID 31621054, PMID 32632956, PMID 38518549, PMID 41651641
2016 (1), 2018 (1), 2019 (1)